MedTrace Logo

Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy

NCT02203565 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-07-26

Study results available
· View outcomes & findings →

Summary

This pilot clinical trial studies Dakin's solution in preventing radiation dermatitis in patients with breast cancer undergoing radiation therapy. Radiation dermatitis is a skin condition in which the affected skin becomes painful, red, itchy, and blistered. Dakin's solution may help reduce dermatitis caused by radiation therapy.

Conditions

Interventions

DRUG

Dakin's solution

Applied topically

RADIATION

radiation therapy

Undergo radiation therapy

OTHER

questionnaire administration

Ancillary studies

OTHER

laboratory biomarker analysis

Optional correlative studies

Sponsors & Collaborators

Principal Investigators

  • Kathleen Horst · Stanford University Hospitals and Clinics

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-07-07
Completion
2016-07-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02203565 on ClinicalTrials.gov